Acid-Suppressive Effects of Various Regimens of Omeprazole in Helicobacter pylori-Negative CYP2C19 Homozygous Extensive Metabolizers: Which Regimen Has the Strongest Effect?

被引:0
作者
Tomohiko Shimatani
Tomoko Kuroiwa
Mutsuko Moriwaki
Jing Xu
Susumu Tazuma
Masaki Inoue
机构
[1] Hiroshima University Hospital,Department of General Medicine
[2] Hiroshima University,Department of Geriatric Health Sciences, Graduate School of Health Sciences
[3] Hiroshima Prefectural Akitsu Hospital,Department of Internal Medicine
来源
Digestive Diseases and Sciences | 2007年 / 52卷
关键词
Omeprazole; CYP2C19; Homozygous extensive metabolizer; Intragastric pH; Divided dose;
D O I
暂无
中图分类号
学科分类号
摘要
To achieve more potent and long-lasting acid suppression, omeprazole was administered for 7 days in 5 regimens: 10, 20, and 40 mg once daily (od), and 10 and 20 mg twice daily (bid), in 7 healthy Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers, and intragastric pH was continuously measured. The median intragastric pH and percent time pH > 4.0 for 24 hours increased dose dependently with 10, 20, and 40 mg od. Ten and 20 mg bid wre comparable to 20 and 40 mg od, respectively. Concerning percent time pH > 4.0 in the nighttime (20:00–8:00 hours), 20 mg bid was significantly superior to 40 mg od (P < .05). In 4 of the 5 regimens, all 7 subjects had nocturnal acid breakthrough, whereas with 20 mg bid it occurred in only 3. We concluded that, considering nighttime acid suppression, omeprazole 20 mg bid had the strongest effect.
引用
收藏
页码:2826 / 2832
页数:6
相关论文
共 233 条
  • [1] Sachs G(1989)The gastric H+,K+-ATPase: the site of action of omeprazole Scand J Gastroenterol (Suppl) 166 3-11
  • [2] Wallmark B(1995)The pharmacology of the gastric acid pump: the H+,K+ ATPase Annu Rev Pharmacol Toxicol 35 277-305
  • [3] Sachs G(1990)Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations Gut 31 968-972
  • [4] Shin JM(1992)Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine J Clin Gastroenterol 15 192-198
  • [5] Briving C(1994)Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety Gut 35 590-598
  • [6] Wallmark B(1994)Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group Gastroenterology 107 1305-1311
  • [7] Hersey S(1995)A comparison of five maintenance therapies for reflux esophagitis N Engl J Med 333 1106-1110
  • [8] Bate CM(1987)Patterns of acid reflux in complicated oesophagitis Gut 28 1484-1488
  • [9] Keeling PW(2001)Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis J Gastroenterol Hepatol 16 1191-1196
  • [10] O’Morain C(2005)Review article: putting immediate-release proton-pump inhibitors into clinical practice—improving nocturnal acid control and avoiding the possible complications of excessive acid exposure Aliment Pharmacol Ther 22 31-38